CAS 677007-74-8

Avatrombopag Meleate

CAS: 677007-74-8

Fórmula: C₃₃H₃₈Cl₂N₆O₇S₂

Pureza: 98%

Peso molecular: 765.7268

Ref: IN-DA01V5CK

1-(3-Chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid maleate

CAS: 677007-74-8

1-(3-Chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid maleate

Pureza: 98%

Peso molecular: 765.74g/mol

Ref: 54-OR1067426

Avatrombopag maleate

CAS: 677007-74-8

Avatrombopag (AKR-501/E5501) is an oral TPO receptor agonist for thrombocytopenia treatment, approved in 2018.

Fórmula: C₃₃H₃₈Cl₂N₆O₇S₂

Cor e Forma: Solid

Peso molecular: 765.72

Ref: TM-T68888

Avatrombopag Maleate

Produto Controlado

CAS: 677007-74-8

Fórmula: C₂₉H₃₄Cl₂N₆O₃S₂·C₄H₄O₄

Cor e Forma: Neat

Peso molecular: 765.72

Ref: TR-A819920

Avatrombopag maleate

CAS: 677007-74-8

Avatrombopag maleate is a small molecule that activates platelets by binding to the beta-granule protein receptor. This drug has been shown to improve blood clotting and lower the need for blood transfusions in patients with thrombocytopenia, which is a condition where there are fewer than normal numbers of platelets in the blood. Avatrombopag maleate has also been shown to reduce brain infarct volume after stroke, suggesting that it may be useful for treating ischemic stroke.

Fórmula: C₃₃H₃₈Cl₂N₆O₇S₂

Pureza: Min. 95%

Peso molecular: 765.7 g/mol

Ref: 3D-CCB00774